Phase 1/2 trial of copanlisib in combination with nivolumab for microsatellite stable ( MSS) colorectal cancer (CRC)

被引：0
|
作者：
Christenson, Eric S.
Wala, Jeremiah A.
Parkinson, Rose
Collins, Natalie B.
Jakubowski, Christopher
Lin, Jea-Ren
Wang, Hao
Ho, Won Jin
Chan, Sabrina
Klein, Rachel
Cetasaan, Yvette
Johnson, Emma
Berg, Maureen
Meyerhardt, Jeffrey
Schlechter, Benjamin
Singh, Harshabad
Sorger, Peter K.
Giannakis, Marios
Azad, Nilofer
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT007
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Results of a phase II study evaluating trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
    Patel, Manish R.
    Falchook, Gerald Steven
    Hamada, Kensuke
    Makris, Lukas
    Winkler, Robert E.
    Gordon, Gilad Shalag
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [32] Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
    Elez, Elena
    Cubillo, Antonio
    Alfonso, Pilar Garcia
    Middleton, Mark R.
    Chau, Ian
    Alkuzweny, Baha
    Alcasid, Ann
    Zhang, Xiaosong
    Van Cutsem, Eric
    BMC CANCER, 2024, 24 (01)
  • [33] Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.
    Bendell, Johanna C.
    Kopetz, Scott
    Middleton, Mark R.
    Eves, P. Taylor
    Bozon, Viviana
    Boyd, Adam P.
    Schellens, Jan H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [34] Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
    Bullock, A.
    Fakih, M.
    Gordon, M.
    Tsimberidou, A.
    El-Khoueiry, A.
    Wilky, B.
    Pimentel, A.
    Margolin, K.
    Mahadevan, D.
    Balmanoukian, A.
    Sanborn, R.
    Schwartz, G.
    Abou-Alfa, G.
    Bockorny, B.
    Moser, J.
    Sharma, S.
    Grossman, J.
    Rosenthal, K.
    O'Day, S.
    Lenz, H.
    Schlechter, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S178 - S179
  • [35] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Bocobo, Andrea Grace
    Wang, Renee
    Behr, Spencer
    Carnevale, Julia C.
    Cinar, Pelin
    Collisson, Eric Andrew
    Fong, Lawrence
    Keenan, Bridget P.
    Kidder, Wesley Allen
    Ko, Andrew H.
    Kolli, Kanti Pallav
    Kennedy, Megan
    Laffan, Angela
    Piawah, Sorbarikor
    Pollak, Marin
    Schwartz, Gabriel
    Whitman, Julia
    Zhang, Li
    Van Loon, Katherine
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A)
    Diamond, J. R.
    Standifer, N.
    Ascierto, M. L.
    Morehouse, C.
    Ghadially, H.
    Canales, J. Rodriguez
    Rebelatto, M. C.
    Naidoo, J.
    Mazzarella, L.
    Patel, S.
    Flor Oncala, M. J.
    Alonso Gordoa, T.
    Wang, D.
    Song, X.
    Jones, D. C.
    Li, X.
    Marshall, S.
    Abdullah, S.
    Jure-Kunkel, M.
    Hellmann, M. D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer
    Morris, Van K.
    Parseghian, Christine Megerdichian
    Escano, Michelle
    Johnson, Benny
    Raghav, Kanwal Pratap Singh
    Dasari, Arvind
    Huey, Ryan
    Overman, Michael J.
    Willis, Jason
    Lee, Michael Sangmin
    Wolff, Robert A.
    Kee, Bryan K.
    Shen, John Paul Y. C.
    Morelli, Maria Pia
    Tam, Alda
    Foo, Wai Chin
    Xiao, Lianchun
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [38] Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
    Wang, Chongkai
    Chevalier, Dawnyel
    Saluja, Janelle
    Sandhu, Jaideep
    Lau, Cecilia
    Fakih, Marwan
    ONCOLOGIST, 2020, 25 (08): : E1188 - E1194
  • [39] A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer
    Koenig, Julie L.
    Pappas, Leon
    Yeap, Beow Y.
    Clark, Jeffrey William
    Klempner, Samuel J.
    Ryan, David P.
    Allen, Jill N.
    Blaszkowsky, Lawrence Scott
    Giantonio, Bruce J.
    Perez, Kimberly
    Schlechter, Benjamin L.
    Wo, Jennifer Yon-Li
    Roberts, Hannah Johnson
    Meyerhardt, Jeffrey A.
    Ludes, Sydney D.
    Zecca, Katharine
    Drapek, Lorraine C.
    Mehta, Arnav
    Hong, Theodore S.
    Parikh, Aparna Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Lee, Michael Sangmin
    Loehrer, Patrick J.
    Imanirad, Iman
    Cohen, Stacey
    Ciombor, Kristen Keon
    Moore, Dominic T.
    Carlson, Cheryl Ann
    Sanoff, Hanna Kelly
    McRee, Autumn Jackson
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345